Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Total Current Liabilities (2017 - 2025)

Dr Reddys Laboratories (RDY) has 8 years of Total Current Liabilities data on record, last reported at $1.2 billion in Q1 2024.

  • For Q1 2024, Total Current Liabilities rose 5668.54% year-over-year to $1.2 billion; the TTM value through Mar 2024 reached $1.2 billion, up 5668.54%, while the annual FY2025 figure was $1.5 billion, 31.62% up from the prior year.
  • Total Current Liabilities reached $1.2 billion in Q1 2024 per RDY's latest filing, up from $20.0 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $1.2 billion in Q1 2024 and bottomed at $20.0 million in Q1 2023.
  • Average Total Current Liabilities over 5 years is $258.2 million, with a median of $37.6 million recorded in 2020.
  • Peak YoY movement for Total Current Liabilities: crashed 43.56% in 2022, then surged 5668.54% in 2024.
  • A 5-year view of Total Current Liabilities shows it stood at $37.6 million in 2020, then soared by 30.56% to $49.1 million in 2021, then crashed by 43.56% to $27.7 million in 2022, then decreased by 27.7% to $20.0 million in 2023, then soared by 5668.54% to $1.2 billion in 2024.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $1.2 billion in Q1 2024, $20.0 million in Q1 2023, and $27.7 million in Q1 2022.